12:11 PM EDT, 04/26/2024 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday it received the European Commission's approval for Kalydeco, or ivacaftor, to treat infants with cystic fibrosis aged one month and older.

Cystic fibrosis is a rare, life-shortening multi-organ genetic disease.

The company said eligible patients will have access to the expanded indication of Kalydeco shortly following the approval.

Price: 398.67, Change: +0.97, Percent Change: +0.24